Solid Biosciences stock (US8317541063): Piper Sandler raises price target to $18

Piper Sandler maintained its Overweight rating on Solid Biosciences while lifting the price target to $18, signaling optimism for the biotech's gene therapy pipeline amid developments in treating Duchenne muscular dystrophy.

Solid Biosciences saw a positive analyst update as Piper Sandler maintained its Overweight rating and raised the price target to $18 from a prior level, according to GuruFocus as of recent update. This reflects growing confidence in the company's gene therapy advancements for serious conditions like Duchenne muscular dystrophy (DMD) and Friedreich's ataxia.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Solid Biosciences Inc
• Sector/industry: Biotechnology / Gene Therapy
• Headquarters/country: United States
• Core markets: Gene therapies for neuromuscular diseases
• Key revenue drivers: Clinical pipeline milestones, partnerships
• Home exchange/listing venue: Nasdaq (SLDB)
• Trading currency: USD

Solid Biosciences: core business model

Solid Biosciences Inc focuses on developing gene therapies for neuromuscular and cardiac diseases. The company advances a portfolio of engineered genetic medicines designed to address unmet needs in rare diseases, primarily through its proprietary platform that enables targeted delivery of therapeutic genes. This approach aims to provide durable treatments with single-dose potential, differentiating it in the competitive biotech landscape.

Headquartered in the US, Solid Biosciences trades on Nasdaq under the ticker SLDB. Its lead programs target Duchenne muscular dystrophy, a severe genetic disorder affecting young boys, highlighting its commitment to high-impact areas with significant patient populations in the US and globally.

Main revenue and product drivers for Solid Biosciences

Pipeline progression remains the primary value driver for Solid Biosciences, with key candidates in clinical development for DMD and Friedreich's ataxia. Milestone payments from partnerships, potential regulatory approvals, and commercialization of approved therapies would fuel future revenue. The company's emphasis on next-generation gene therapy platforms positions it to capture growth in the expanding US gene therapy market, projected to reach substantial sizes per industry reports.

Recent analyst optimism from Piper Sandler underscores potential in these programs, particularly as clinical data emerges. For US investors, exposure to innovative biotech with Nasdaq listing offers direct access to this high-growth sector.

Industry trends and competitive position

The gene therapy sector continues to expand, driven by technological advances and increasing FDA approvals for rare disease treatments. Solid Biosciences competes with established players but differentiates through its delivery innovations tailored for muscle tissues, critical for DMD. US market leadership in biotech funding supports such companies, with North Carolina and Massachusetts hubs fostering talent and infrastructure relevant to Solid Biosciences' operations.

Conclusion

Solid Biosciences continues to advance its gene therapy pipeline amid positive analyst feedback from Piper Sandler, which maintained Overweight and raised its target to $18. The focus on DMD and related indications positions the company in a vital US biotech niche. Investors track clinical milestones and market dynamics closely as developments unfold.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.